Friday, 19 Jul 2019

You are here

EULAR: Tofacitinib Effective in Ankylosing Spondylitis

Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis. Both tofacitinib 5 and 10 mg BID demonstrated greater clinical efficacy compared with placebo as measured by ASDAS20 and ASDAS40 outcomes. Additionally, MRI imaging showed structural/inflammatory benefits in TOFA, but not placebo treated patients.

208 AS patients were randomised 1:1:1:1 to placebo or tofacitinib 2, 5 or 10 mg BID for 12 weeks plus 4 weeks follow-up. There were 196 completers, and 87% were HLA-B27 positive and 81% were white. The mean disease duration was 6.3 years and the mean baseline BASDAI was 6.7. 

Treatment with TOFA (5 mg or 10 mg bid) yielded better ASDAS20 scores that were 23% adn 27% better than placebo rates (~40%).  BASDAI results were similar.  The ineffective 2 mg bid dose of TOFA had results comparable to placebo. No new safety signals were raised by this trial. 

MRI changes were assessed by SPARCC scoring of the sacroiliac joints and spine. Overall, the 5mg and 10 mg TOFA group yielded significantly less change and inflammation in the spine.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis

Correlates with fatigue were assessed in psoriatic arthritis (PsA) patients in the DANBIO registry and found to be associated with  clinical inflammatory factors, disease duration, and chronic pain.

A toital of 2062 PsA patients in the Danish nationwide registry DANBIO were studied by cross-sectional survey from December 2013 to June 2014.

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.

Recommendations for Exercise in Ankylosing Spondylitis

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

Biologic Retention in Ankylosing Spondylitis Patients

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

A nationwide Swedish Rheumatology register followed 2590 Bio-naïve AS who started a TNFi between 2006–2015.

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.